source
- Dimerix snaps up Mission’s stalled, phase 2-ready kidney disease candidate in $292M dealDimerix has bought an acute kidney injury drug from Mission Therapeutics, paying $5 million upfront and committing up to $287 million in milestones for the phase 2-ready asset.Fierce Biotech · 14d ago↗ source
- Catheter Introducer Kit Recall: Abiomed Removes 14Fr Low Profile Introducer KitsProlonged use of the Abiomed 14Fr Low Profile Introducer may lead to thrombus formation.fda medwatch · 14d ago↗ source
- Thoracic Stent Graft Recall: Bolton Medical Removes Relay Pro SystemAffected grafts may not unclasp from the delivery system. This may require conversion to open surgical repair and can result in patient death.